Recent safety notifications regarding personal care and OTC drug products have highlighted a significant nationwide recall involving DermaRite Industries, LLC. This action, which saw a major expansion in late 2025, remains a critical point of concern for healthcare facilities, nursing homes, and home caregivers in 2026. The focus of this voluntary recall is the potential contamination with the Burkholderia cepacia complex (BCC), a group of bacteria that poses varying degrees of risk depending on an individual's health status.

The scope of this recall is extensive, covering a wide array of products ranging from antiseptic soaps and hand sanitizers to skin protectants and moisturizing lotions distributed throughout the United States and Puerto Rico. Understanding which products are affected and the nature of the microbial risk is essential for maintaining safety standards in any environment where these supplies are utilized.

The nature of the Burkholderia cepacia risk

Burkholderia cepacia is not a single organism but a group of bacteria often found in soil and water. In the context of manufactured topical products, its presence is a serious compliance and safety failure. For most healthy individuals, exposure to BCC through the skin might result in no symptoms or perhaps a minor, localized infection if the skin is broken or compromised by a lesion.

However, the risk profile changes drastically for vulnerable populations. In clinical settings, individuals who are immunosuppressed or suffering from chronic lung diseases (such as cystic fibrosis) are at extreme risk. If BCC enters the bloodstream—potentially through use on compromised skin or during the care of someone with an intravenous line—it can lead to life-threatening sepsis. Sepsis is a systemic inflammatory response that can cause organ failure and death. Because many DermaRite products are specifically designed for the elderly, the bed-bound, or those with fragile skin, the potential for these products to reach high-risk individuals is significant.

Furthermore, BCC is known for its resilience. It can survive in challenging environments and is often resistant to many common antibiotics, making any infection it causes difficult to treat. This is why the presence of the bacteria in topical cleansers or protectants necessitates a full-scale recall rather than simple monitoring.

Catalog of affected DermaRite products

The recall expanded significantly from its initial stages to include dozens of items under the DermaRite brand. Facilities should cross-reference their current inventory against the following categories of affected products. Note that for many of these, the recall applies to all lots with expiry dates on or before August 2027.

Cleansers and body washes

Cleansing products used in bed-bath scenarios or for daily hygiene are a primary concern because they are used over large surface areas of the body.

  • 3-n-1 Cleansing Foam: A thick, rinse-free foam used as a body wash, shampoo, and perineal cleanser. Its use on fragile skin makes any bacterial presence particularly hazardous.
  • Clean-N-Free: A mild, rinse-free wash frequently used for bed-bound patients. Since it is designed to clean without water, any bacteria in the solution remains on the skin surface.
  • Derma Rain: An extra-mild, dye-free body wash and shampoo. Its pH-balanced formula is intended for sensitive skin types, which are more susceptible to irritation and micro-tears.
  • Derma Vera: A full-body cleanser enriched with shea butter. It is commonly used in long-term care facilities for routine hair and skin care.
  • Renew Full Body Wash & Shampoo: A versatile cleanser with a light fruit fragrance, often utilized in perineal care.
  • Total Bath and Total Foam: Head-to-toe cleansers enriched with Vitamin E. These are mainstay products in many healthcare supply rooms.

Antiseptic soaps and hand hygiene

Products intended to reduce bacteria on the skin are ironically included in this recall due to their own potential bacterial contamination.

  • Derma Kleen: An OTC healthcare antiseptic lotion soap containing Vitamin E. It is primarily indicated for hand washing to decrease bacteria.
  • Kleen Foam: An antimicrobial foam soap with aloe vera. It is often used after diaper changes or when assisting ill individuals.
  • Gel Rite and Hand-E-Foam: These are alcohol-based and foaming hand sanitizers. While high concentrations of alcohol typically inhibit bacterial growth, certain strains of BCC can be surprisingly hardy, and the recall serves as a preventative measure for all lots identified.
  • San-E-Foam: Another foaming hand sanitizer intended for repeated use in clinical environments.

Skin protectants and specialized creams

These products are designed to stay on the skin for extended periods, often under occlusion (like under a diaper or bandage), which can create an environment where bacteria might thrive.

  • 4-n-1 Wash Cream: Used to protect and help relieve chafed or cracked skin. Applying a contaminated product to already cracked skin provides a direct pathway for infection.
  • Dermacerin: A moisturizing cream for dry, chapped, or cracked skin. It is frequently used to combat the effects of wind and cold weather.
  • DermaFungal: An OTC antifungal cream used for athlete’s foot, jock itch, and ringworm. Because this is applied to skin already suffering from a fungal infection, the barrier is often compromised.
  • DermaMed: A protectant used for oozing or weeping skin caused by poison ivy, oak, or sumac.
  • PeriGuard: A widely used ointment in incontinence care, designed to seal out wetness and prevent rashes. The use of this product in the perineal area on irritated skin is a high-risk scenario if BCC is present.
  • Renew Dimethicone and Renew PeriProtect: These skin protectants are specifically formulated for treating and preventing diaper rash.
  • Renew Skin Repair: A cream used for face, hands, and legs to relieve chapped skin.

Incontinence and perineal care cleansers

Perineal care is a sensitive aspect of patient hygiene where the risk of secondary infection is always a concern for caregivers.

  • PeriGiene: An antiseptic cleanser specifically indicated for the perineal area.
  • PeriFresh: A mild cleanser spray designed to deodorize and nourish skin following incontinence episodes.

Identifying recalled lots and expiration dates

The complexity of this recall lies in the sheer number of affected batches. While the initial recall focused on specific individual lots of DermaKleen, DermaSarra, and KleenFoam, the expanded notice covers almost the entire product line for specific timeframes.

Caregivers and procurement officers should look for the "Lot Number" and "Expiration Date" usually printed on the bottom of bottles or on the crimp seal of tubes. For the majority of the expanded list, any product with an expiration date on or before August 2027 should be treated as potentially affected.

If you are a consumer or facility manager, the first step is to isolate these products. Moving them to a "quarantine" area prevents accidental use while you determine the next steps for disposal or return.

What products are safe to use?

It is equally important to identify what has not been recalled to avoid disrupting essential patient care unnecessarily. DermaRite has confirmed that several of their high-volume categories remain unaffected and safe for continued use according to their standard indications:

  1. Wound Care Products: This includes specialized dressings, hydrogels (like DermaSyn, provided they are not from the specific recalled lots if mentioned elsewhere), and advanced wound care solutions. However, always check specific lot numbers for DermaSyn as some specific lots were included in the broader expansion.
  2. Nutritional Products: Any dietary supplements or nutritional liquids provided by the company are not part of this microbial contamination recall.

By focusing the recall on topical personal care and OTC drug products, the company aims to resolve the specific manufacturing issue related to the BCC contamination without stripping facilities of their entire wound management inventory.

Procedural steps for healthcare facilities

For hospitals, long-term care facilities, and hospice providers, the management of a recall of this scale requires a systematic approach. The presence of these products in a facility is not just a logistical issue but a patient safety and liability concern.

Inventory audit and isolation

Designated staff should conduct a sweep of all supply closets, patient rooms, and medication carts. Even small "travel size" samples or individual packets should be checked. Once identified, the products must be removed from the point of care immediately. Placing them in a box labeled "RECALLED - DO NOT USE" is a standard safety protocol.

Destruction and documentation

DermaRite’s instructions typically advise distributors and customers to destroy the affected inventory in accordance with the facility's standard waste disposal process. However, it is vital to document the quantity and lot numbers of the destroyed items. This documentation is necessary for potential credit, insurance claims, and to prove compliance during future health inspections.

Communication with staff and patients

Staff need to be informed of the substitute products available so that patient care remains seamless. If a patient has been using one of the recalled products and develops signs of a skin infection or systemic illness (fever, chills, lethargy), medical providers should be notified immediately. Mentioning the potential exposure to Burkholderia cepacia can help doctors choose the correct diagnostic tests and antibiotic treatments.

Advice for home users and individual consumers

If you have purchased DermaRite products for personal use or for a family member at home, you should stop using them immediately. Even if the product looks and smells normal, the bacteria are invisible to the naked eye.

  • Disposal: You can dispose of these products in your regular household trash. It is often recommended to pour liquid products into a sealable bag with an absorbent material (like coffee grounds or kitty litter) to prevent them from being used by others if they are found in the trash.
  • Monitoring Health: Keep a close watch on the skin where the product was applied. If you notice redness, swelling, or pus, or if the person using the product develops a fever, contact a healthcare professional. Be sure to inform them of the product's name and the reason for the recall.
  • Reporting: Consumers are encouraged to report any adverse events or quality problems to the FDA’s MedWatch program. This helps the government track the scope of the issue and ensures manufacturer accountability.

Professional support and contact information

Managing the returns or questions regarding this recall has been outsourced to specialized firms to handle the high volume of inquiries.

  • For general questions and recall management: You can contact the designated recall coordinator, Sedgwick, at 888-943-5190. They operate during standard business hours (8:00 am – 5:00 pm EST, Monday through Friday).
  • Email correspondence: Inquiries can be directed to the specific recall email address: dermarite5186@sedgwick.com.
  • Specific lot questions: For older lot-specific inquiries from the initial August 2025 announcement, the company had previously utilized voluntary.action@dermarite.com, though the Sedgwick contact is now the primary channel for the expanded recall.

Long-term implications for product safety

This event serves as a reminder of the vulnerability of the supply chain for topical OTC drugs. While these products are not as stringently regulated as injectable medications, they are used on the most vulnerable members of society. The expansion of the recall "out of an abundance of caution" suggests that the manufacturer is taking the potential for systemic contamination seriously.

For facilities, this might be a time to review the preservatives and antimicrobial efficacy of the brands they choose. For the manufacturer, the path forward involves rigorous testing and potentially redesigning manufacturing lines to ensure that water systems and raw materials are free from the Burkholderia cepacia complex.

As of early 2026, the priority remains the removal of every single affected bottle from the market. Vigilance in checking expiry dates—especially that August 2027 threshold—is the most effective way to prevent the serious health complications associated with this contamination. By staying informed and acting decisively, caregivers can ensure that the tools they use to heal and clean do not inadvertently cause harm.